Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 12:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Parkinson Disease
Interventions
Requip PR, Mirapex
Drug
Lead sponsor
Rajesh Pahwa, MD
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Parkinson Disease
Interventions
Placebo, Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Sun City, Arizona • Tempe, Arizona • La Jolla, California + 7 more
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, Dexpramipexole 50 mg/day, Dexpramipexole 150 mg/day, Dexpramipexole 300 mg/day
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
21 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 18 more
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
levodopa, Mirapex (pramipexole), [123I]ß-CIT and SPECT imaging
Drug · Procedure
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
Oxnard, California • Englewood, Colorado • New Haven, Connecticut + 9 more
Conditions
Treatment Resistant Depression
Interventions
Discontinuation of serotonergic antidepressants, Continuation of serotonergic medications
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
PTSD, MDD
Interventions
PE/Pramipexole
Combination Product
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy Volunteers
Interventions
Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Amyotrophic Lateral Sclerosis
Interventions
R(+) pramipexole dihydrochloride monohydrate
Drug
Lead sponsor
Bennett, James P., Jr., M.D., Ph.D.
Individual
Eligibility
21 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Charlottesville, Virginia
Conditions
Restless Legs Syndrome
Interventions
pregabalin, placebo, pramipexole
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions

NCT01074463
Conditions
Healthy
Interventions
Pramipexole Dihydrochloride
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Tourette Syndrome
Interventions
pramipexole 0.125 mg BID, pramipexole 0.0625 mg QD, pramipexole 0.125 mg TID, pramipexole 0.25 mg BID, pramipexole 0.0625 mg BID
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
13
States / cities
Bradenton, Florida • Tampa, Florida • Columbus, Georgia + 9 more
Conditions
Idiopathic Parkinson Disease
Interventions
CTC-413
Combination Product
Lead sponsor
Chase Therapeutics Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Farmington Hills, Michigan
Conditions
Cocaine Addiction, Cocaine Abuse, Cocaine Dependence, Substance Abuse
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 2 Interventional Results available

Lexapro and Pramipexole and to Treat Major Depression

NCT00086307
Conditions
Major Depression
Interventions
Pramipexole, Escitalopram
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Tourette Syndrome
Interventions
pramipexole immediate release (IR), Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
14
States / cities
Bradenton, Florida • Tampa, Florida • Columbus, Georgia + 10 more
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

NCT01597310
Conditions
Healthy Volunteers
Interventions
Warfarin, Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Phase 3 Interventional Results available

Phase 3 Study of Dexpramipexole in ALS

NCT01281189
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
43
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 39 more
Conditions
Parkinson's Disease
Interventions
No intervention.
Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Rochester, New York
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years to 75 Years
Enrollment
3,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
36
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Sun City, Arizona + 31 more
Active, not recruiting Phase 2 Interventional

Pramipexole to Enhance Social Connections

NCT06269146
Conditions
Anxiety Disorders, Anxiety, Depression, Social Disconnection
Interventions
Pramipexole Pill, Placebo Pill
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
San Diego, California • New York, New York
Conditions
Eosinophilic Asthma, Asthma
Interventions
Dexpramipexole, Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 74 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
36
States / cities
Los Angeles, California • Mission Viejo, California • Westminster, California + 30 more
Terminated Phase 3 Interventional Results available

Phase 3 Extension Study of Dexpramipexole in ALS

NCT01622088
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Phoenix, Arizona • Fresno, California • Orange, California + 38 more
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole SAD/MAD Study

NCT01449578
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Dexpramipexole Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Active, not recruiting Phase 3 Interventional

Infusion of Apomorphine: Long-term Safety Study

NCT02339064
Conditions
Idiopathic Parkinson's Disease
Interventions
apomorphine infusion
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more